ESC 365 - P2Y12 inhibition should be started at the time of NSTEMI diagnosis - CON.

ESC Premium Access

P2Y12 inhibition should be started at the time of NSTEMI diagnosis - CON.

Session: Controversies in anti-platelet therapy

Topic: Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)

Speaker: Professor G. Montalescot (Paris, FR)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor Gilles Montalescot

Pitie Salpetriere APHP University Hospital, Paris (France)

35 presentations

1 follower

5 more presentations in this session

P2Y12 inhibition should be started at the time of NSTEMI diagnosis - PRO.

Speaker: Professor M. Valgimigli (Lugano, CH)

P2Y12 inhibition should be started at the time of NSTEMI diagnosis -Discussion

Duration of DAPT should be beyond 1 year post acute coronary syndrome - PRO.

Speaker: Doctor M. Bonaca (Aurora, US)

Duration of DAPT should be beyond 1 year post acute coronary syndrome - CON.

Speaker: Professor G. De Luca (Messina, IT)

Duration of DAPT should be beyond 1 year post acute coronary syndrome - Discussion

Access the full session

Controversies in anti-platelet therapy

Speakers: Professor G. Montalescot, Professor M. Valgimigli, Doctor M. Bonaca, Professor G. De Luca

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources